2001
Myocardial Revascularization as a Therapeutic Strategy in the Patient with Advanced Ventricular Dysfunction
Mitropoulos F, Elefteriades J. Myocardial Revascularization as a Therapeutic Strategy in the Patient with Advanced Ventricular Dysfunction. Heart Failure Reviews 2001, 6: 163-175. PMID: 11391034, DOI: 10.1023/a:1011416929501.Peer-Reviewed Original ResearchConceptsCoronary artery bypassVentricular dysfunctionArtery bypassPerioperative managementEjection fractionPatient selectionAdvanced ventricular dysfunctionRight ventricular dysfunctionLeft ventricular dysfunctionLow ejection fractionOptimal perioperative managementSevere ventricular dysfunctionCareful patient selectionCoronary artery diseaseLong-term outcomesNumber of patientsQuality of lifeSurgical revascularizationHeart transplantationPulmonary hypertensionMyocardial revascularizationOverall prognosisArtery diseaseMedical managementRedo bypass
1999
Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass
Fitch J, Rollins S, Matis L, Alford B, Aranki S, Collard C, Dewar M, Elefteriades J, Hines R, Kopf G, Kraker P, Li L, O’Hara R, Rinder C, Rinder H, Shaw R, Smith B, Stahl G, Shernan S. Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass. Circulation 1999, 100: 2499-2506. PMID: 10604887, DOI: 10.1161/01.cir.100.25.2499.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBlood Loss, SurgicalCardiopulmonary BypassCognition DisordersComplement ActivationComplement C5Complement Membrane Attack ComplexCoronary Artery BypassCoronary DiseaseCreatine KinaseHumansInflammationIsoenzymesMiddle AgedMyocardial Reperfusion InjuryPostoperative ComplicationsProspective StudiesPsychological TestsSingle-Chain AntibodiesConceptsMini-Mental State ExaminationPathological complement activationCardiopulmonary bypassBlood lossMyocardial injuryC5 inhibitionTissue injuryCoronary artery bypass graft surgeryComplement inhibitorsArtery bypass graft surgeryComplement activationCognitive deficitsSingle-chain antibodyC5 complement inhibitorNew cognitive deficitsSignificant dose-dependent inhibitionBypass graft surgeryPostoperative blood lossPostoperative myocardial injurySystemic inflammatory responseComplement-mediated inflammationLeukocyte CD11b expressionNovel therapeutic strategiesComplement hemolytic activityDose-dependent fashion
1997
Results of Coronary Artery Bypass Grafting by a Single Surgeon Patients With Left Ventricular Ejection Fractions ≤30%
Elefteriades J, Morales D, Gradel C, Tollis G, Levi E, Zaret B. Results of Coronary Artery Bypass Grafting by a Single Surgeon Patients With Left Ventricular Ejection Fractions ≤30%. The American Journal Of Cardiology 1997, 79: 1573-1578. PMID: 9202343, DOI: 10.1016/s0002-9149(97)00201-4.Peer-Reviewed Original ResearchConceptsAdvanced LV dysfunctionInternal mammary arteryCoronary artery diseaseEjection fractionLV dysfunctionMammary arteryArtery diseaseCongestive heart failure classSevere left ventricular dysfunctionCoronary Artery Bypass GraftingBetter long-term survivalHeart failure classSingle surgeon's patientsArtery Bypass GraftingCoronary artery bypassHigh operative riskLeft ventricular dysfunctionSevere ventricular arrhythmiasLV ejection fractionVentricular ejection fractionUse of CABGLong-term survivalQuality of lifeAngina classArtery bypass
1995
Cabg in Advanced Left Ventricular Dysfunction
Elefteriades J, Kron I. Cabg in Advanced Left Ventricular Dysfunction. Cardiology Clinics 1995, 13: 35-42. PMID: 7796430, DOI: 10.1016/s0733-8651(18)30060-2.Peer-Reviewed Original ResearchConceptsAdvanced left ventricular dysfunctionCongestive heart failure stateAdvanced ischemic cardiomyopathyEjection fraction increaseIndependent clinical seriesInternal mammary conduitsHeart failure stateLeft ventricular dysfunctionHeart transplantationVentricular dysfunctionIschemic cardiomyopathyPatient groupClinical seriesIschemic muscleCABGPatientsLong-term longevityMuscleUniversity of VirginiaTransplantationCardiomyopathyDysfunctionImportant role
1990
Heart-lung transplantation: initial experience in New England.
Letsou G, Franco K, Kopf G, Dewar M, Elefteriades J, Hammond G, Baldwin J. Heart-lung transplantation: initial experience in New England. Connecticut Medicine 1990, 54: 419-24. PMID: 2225808.Peer-Reviewed Original ResearchConceptsPulmonary hypertensionEnd-stage cardiopulmonary diseaseAssociated pulmonary hypertensionNormal cardiopulmonary functionHeart-lung transplantationHeart-lung transplantsPrimary pulmonary hypertensionDoxorubicin-induced cardiomyopathyPulse steroidsRejection episodesDonor surgeryFluid overloadCardiopulmonary bypassCardiopulmonary functionCardiopulmonary diseaseEffective therapyPrimary disorderFunctional capacityPatientsCystic fibrosisInitial experienceGraftAge 33HypertensionAge 16
1988
Recovery of severe ischemic ventricular dysfunction after coronary artery bypass grafting
Brill D, Deckelbaum L, Remetz M, Soufer R, Elefteriades J, Zaret B. Recovery of severe ischemic ventricular dysfunction after coronary artery bypass grafting. The American Journal Of Cardiology 1988, 61: 650-651. PMID: 3257840, DOI: 10.1016/0002-9149(88)90784-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultCoronary Artery BypassCoronary DiseaseHeartHeart VentriclesHumansMaleMyocardial ContractionStroke VolumeConceptsWall motion abnormalitiesVentricular dysfunctionLeft ventricularMotion abnormalitiesReversible wall motion abnormalitiesSevere coronary artery diseaseVentricular wall motion abnormalitiesIschemic ventricular dysfunctionReversible ventricular dysfunctionCoronary artery bypassCoronary artery diseasePeriod of ischemiaArtery bypassIschemic dysfunctionArtery diseaseHibernating myocardiumMyocardial infarctionMyocardial scarDysfunctionFibrous tissueRecent evidencePatientsComplete reversalAbnormalitiesRevascularization